China Expands Medical Coverage with 199 New Drugs in 2026
China adds 199 innovative drugs to national medical insurance, benefiting 1.17 billion patients and driving 740 billion yuan in sales by 2026.
Pharmaceuticals
Trump Slaps 100% Tariff on Key Pharma Imports, Effective 2026
US imposes 100% tariffs on select pharmaceuticals starting July 2026, with exemptions for generics and tiered rates for allied nations. Analysis of global trade implications.
China Rivals US in Biotech Innovation, Says Novartis CEO at Davos 2026
Novartis CEO Vasant Narasimhan highlights China’s biotech advancements at Davos 2026, noting parity with US innovation and future growth potential.
Premier Li Qiang Calls for Stringent Regulation of Enterprise Inspections
Chinese Premier Li Qiang has urged strict regulation of enterprise inspections to stabilize market expectations and enhance governance, following a State Council meeting that approved key guidelines and reforms.
AstraZeneca to Launch 100 New Medicines in China, Boosting Shanghai R&D Collaboration
AstraZeneca plans to launch over 100 new medicines in China within five years, strengthening collaboration through its Shanghai R&D center, according to EVP Sharon Barr.
AstraZeneca Deepens Roots in China’s Pharmaceutical Landscape
AstraZeneca amplifies its presence in China with significant investments in Wuxi and Qingdao, focusing on innovation and R&D to advance global health and economic growth.
U.S. Opioid Crisis: Pharmaceutical Companies Under Fire
The over-prescription of opioids in the U.S. has led to a major addiction crisis, with pharmaceutical companies accused of underplaying addiction risks while exaggerating benefits.